Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops a new class of injectable therapeutics. These therapeutics are engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. The company's Immuno-STAT® platform is designed to selectively modulate disease-relevant T cells, aiming to enhance efficacy while minimizing off-target effects. Cue Biopharma's programs include several drug product candidates: * **CUE-400 series (Autoimmune Diseases):** These candidates, such as CUE-401 for autoimmune conditions, exploit transforming growth factor beta (TGF-β) and Interleukin 2 (IL-2) signaling. Their mechanism is designed to induce an anti-inflammatory process by fostering the proliferation of regulatory T cells (Tregs) and inducing Tregs from T effector cells, with the potential to restore immune balance and functional immune tolerance. * **CUE-500 series (Targeted Cell Depletion):** An example is CUE-501 for autoimmune B cell depletion, which has been licensed to Boehringer Ingelheim International GmbH. These candidates redirect anti-viral killer T cells to target and eliminate defined pathogenic cells. * **CUE-100 series (Oncology):** This series includes CUE-101 for HPV+ cancers and CUE-102 for Wilms' tumor 1 protein (WT1) expressing cancers. Both of these have been licensed to ImmunoScape Pte. Ltd. for development in oncology indications and are designed to selectively activate and expand tumor-specific T cells. The Immuno-STAT framework is engineered to be highly flexible and modular, allowing for the deployment of similar core functional elements to restore immune balance across various therapeutic approaches.